Mizuho Securities Principal Investment logo

Mizuho Securities Principal Investment

Asia, Tokyo, Japan, Tokyo

Description

Mizuho Securities Principal Investment is the investment arm of Mizuho Securities.

Investor Profile

Mizuho Securities Principal Investment has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (33%)
  • Series C (33%)
  • Corporate Round (33%)

Country Focus

  • United States (67%)
  • Japan (33%)

Industry Focus

  • Medical
  • Health Diagnostics
  • Therapeutics
  • Biotechnology
  • Genetics
  • Health Care
  • Business Information Systems
  • Document Management
  • Information Services
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Mizuho Securities Principal Investment frequently co-invest with?

HBM Healthcare Investments
Europe, Zug, Switzerland, Zug
Co-Investments: 1
Taiwania Capital Management Corporation
Asia, T'ai-pei, Taiwan, Taipei
Co-Investments: 2
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 1
Cobro Ventures
North America, Virginia, United States, Arlington
Co-Investments: 2
RTW Investments
North America, New York, United States, New York
Co-Investments: 2
Bain Capital Life Sciences
North America, Massachusetts, United States, Boston
Co-Investments: 1
3E Bioventures
Asia, Beijing, China, Beijing
Co-Investments: 1
Axil Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 2
CC
North America, New York, United States, New York
Co-Investments: 1

What are some of recent deals done by Mizuho Securities Principal Investment?

C4 Therapeutics

Cambridge, Massachusetts, United States

C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.

Health DiagnosticsMedicalTherapeutics
Series BJun 16, 2020
Frequency Therapeutics

Lexington, Massachusetts, United States

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue.

BiotechnologyGeneticsHealth CareMedical
Series CJul 23, 2019
PeptiStar

Settsu, Osaka, Japan

PeptiStar continually strives to develop novel manufacturing technologies to address needs in every stage of the peptide value chain.

Business Information SystemsDocument ManagementInformation ServicesManufacturing
Corporate RoundApr 18, 2018
Amount Raised: $186,286,291